 In patients with stable clinically unchanged or improved and radiographic disease increase or decrease in tumor size by less than 25 or responding disease clinically unchanged or improved and radiographic disease decrease in size by 50 or more, three additional cycles of SOM230 will be administered, following which patients will be reassessed. 